- Home
- LPCN vs SABS Comparison
LPCN vs SABS Comparison
Compare LPCN & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPCN
- SABS
- Stock Information
- Founded
- LPCN 1997
- SABS 2014
- Country
- LPCN United States
- SABS United States
- Employees
- LPCN N/A
- SABS N/A
- Industry
- LPCN Biotechnology: Pharmaceutical Preparations
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- LPCN Health Care
- SABS Health Care
- Exchange
- LPCN Nasdaq
- SABS Nasdaq
- Market Cap
- LPCN 16.1M
- SABS 15.8M
- IPO Year
- LPCN N/A
- SABS N/A
- Fundamental
- Price
- LPCN $3.17
- SABS $1.81
- Analyst Decision
- LPCN Strong Buy
- SABS Strong Buy
- Analyst Count
- LPCN 2
- SABS 6
- Target Price
- LPCN $9.00
- SABS $11.17
- AVG Volume (30 Days)
- LPCN 71.7K
- SABS 72.7K
- Earning Date
- LPCN 05-08-2025
- SABS 06-17-2025
- Dividend Yield
- LPCN N/A
- SABS N/A
- EPS Growth
- LPCN N/A
- SABS N/A
- EPS
- LPCN N/A
- SABS N/A
- Revenue
- LPCN $3,674,834.00
- SABS $377,835.00
- Revenue This Year
- LPCN N/A
- SABS N/A
- Revenue Next Year
- LPCN N/A
- SABS N/A
- P/E Ratio
- LPCN N/A
- SABS N/A
- Revenue Growth
- LPCN N/A
- SABS N/A
- 52 Week Low
- LPCN $2.68
- SABS $1.00
- 52 Week High
- LPCN $11.79
- SABS $5.01
- Technical
- Relative Strength Index (RSI)
- LPCN 43.78
- SABS 51.92
- Support Level
- LPCN $3.00
- SABS $1.76
- Resistance Level
- LPCN $3.49
- SABS $2.00
- Average True Range (ATR)
- LPCN 0.34
- SABS 0.15
- MACD
- LPCN -0.05
- SABS -0.01
- Stochastic Oscillator
- LPCN 16.50
- SABS 44.93
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.